Hyderabad, Dec. 1
PERLECAN Pharma Pvt Ltd, a joint venture between Dr Reddy's Laboratories, ICICI Venture Funds Management Company Ltd and Citigroup Venture Capital International Mauritius Ltd, has announced the commencement of phase-I clinical trials of its new drug candidate for treatment of obesity `DRL-11605' in Canada.
In a release here on Thursday, Perlecan said the drug candidate is being developed for the treatment of obesity with or without accompanying diabetes and lipid disorders.
Perlecan Pharma received assignment of four new chemical entities (NCEs) from Dr Reddy's Labs, including all titles and rights of the development and commercialisation.
According to the company, obesity is a growing medical problem worldwide and is a major risk factor for development of diabetes and cardiovascular disease.
The company said that DRL-11605 works by a new mechanism that activates all isoforms of PPAR receptors which control fat, lipid and glucose utilisation by the body. It represents one of the first pan-PPAR activators to be developed for treatment of obesity. In animal models of obesity, treatment with DRL-11605 has shown marked reduction in body weight and improvements in blood glucose and lipids, the release said.